Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Second-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia

July 10th 2023

Andrew Brunner, MD, reviews the available second-line treatment options for lower-risk MDS with symptomatic anemia.

Ruxolitinib for the Management of PV

July 10th 2023

Abdulraheem Yacoub, MD, reviews data from the RESPONSE and RESPONSE-2 trials on the use of ruxolitinib for the treatment of polycythemia vera.

Monitoring Treatment With ESAs for Lower-Risk MDS With Symptomatic Anemia

July 10th 2023

Dr Madanat defines erythropoiesis-stimulating agent (ESA) treatment failure in lower-risk MDS with symptomatic anemia and describes his approach to monitoring patients.

Navtemadlin With Ruxolitinib Leads to SVR Benefit in TP53 Wild-Type Myelofibrosis

July 7th 2023

John O. Mascarenhas, MD, discusses the design and rationale of the KRT-232-109 trial, key findings from the trial, and potential future directions of the study.

FDA Lifts Partial Clinical Hold on TakeAim Leukemia Trial of Emavusertib in AML/MDS

July 6th 2023

The FDA has lifted a partial clinical hold on the phase 1/2 TakeAim Leukemia trial evaluating emavusertib monotherapy and in combination with azacitidine and venetoclax in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndrome.

Initiating Treatment for Lower-Risk MDS With Symptomatic Anemia

July 3rd 2023

The panel shares at what point they decide to start treatment for patients with lower-risk MDS and symptomatic anemia.

Selecting a Frontline Therapy for Patients With PV

July 3rd 2023

Jamile Shammo, MD, explains how she decides on the most appropriate treatment option for a patient with polycythemia vera.

First-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia

July 3rd 2023

Yazan Madanat, MD, details the available options for first-line treatment of patients with lower-risk MDS and symptomatic anemia.

Current Treatment Landscape for Patients With PV

July 3rd 2023

Drs Rampal and Yacoub details the currently available treatment options and reviews the rationale for use in patients with PV.

Ropeginterferon Alfa-2b Produces Responses, Safety in Prefibrotic Primary Myelofibrosis

June 30th 2023

Harry Gill, MD, discusses the rationale for exploring ropeginterferon alfa-2b as a potential treatment option for patients early myelofibrosis and expands on the efficacy and safety data observed in the phase 2 study.

Risk Assessment for Patients with Polycythemia Vera (PV)

June 26th 2023

Dr Jamile Shammo describes how risk is assessed for patients with polycythemia vera.

Dr Komrokji on the Classification of Patients With Myelodysplastic Syndromes

June 26th 2023

Rami Komrokji, MD, discusses key findings from an expanded analysis of the classification of patients with myelodysplastic syndromes.

An Overview of Myeloproliferative Neoplasms (MPNs)

June 26th 2023

Experts provide an overview of myeloproliferative neoplasms, including the subtypes, process of diagnosis as well as reviewing the role of biomarkers.

Risk Stratification of MDS

June 26th 2023

Amer Zeidan, MBBS, MHS, explains risk stratification in MDS, how the process has evolved over time, and the guidelines he typically follows.

Diagnosing Myelodysplastic Syndromes (MDS)

June 26th 2023

Hetty Carraway, MD, reviews how MDS is diagnosed and the common symptoms that patients who have MDS may present with.

Dr Mascarenhas on the Initial Efficacy of Navtemadlin Plus Ruxolitinib in Myelofibrosis

June 23rd 2023

John Mascarenhas, MD, discusses initial clinical activity observed with the addition of the first-in-class MDM2 inhibitor navtemadlin to ruxolitinib in primary or secondary myelofibrosis.

New and Anticipated Advances Across Hematologic Malignancies Necessitate Improved Navigation of Current Options

June 23rd 2023

John M. Burke, MD, expands on the use of novel BTK inhibitor regimens in mantle cell lymphoma, treatment sequencing challenges and other unmet needs in diffuse-large B-cell lymphoma, the evolution of management strategies for myeloproliferative neoplasms, and the potential influence of new and emerging therapeutics in chronic lymphocytic leukemia.

Dr Komrokji on Ongoing Studies in Higher- and Lower-Risk MDS

June 21st 2023

Rami Komrokji, MD, discusses ongoing clinical trials in patients with higher- and lower-risk myelodysplastic syndromes.

Pacritinib Provides Spleen, Symptom Reduction Regardless of Blood Counts, Association Between SVR and OS in Myelofibrosis

June 16th 2023

Treatment with the JAK2 inhibitor pacritinib demonstrated comparable improvements in spleen and symptom response regardless of baseline platelet counts and hemoglobin levels, according to findings from the pivotal phase 3 PERSIST-1 and PERSIST-2 trials.

Dr Kremyanskaya on the Efficacy of Rusfertide in Phlebotomy-Dependent Polycythemia Vera

June 16th 2023

Marina Kremyanskaya, MD, PhD, discusses key efficacy data for rusfertide in the phase 2 REVIVE trial of phlebotomy-dependent polycythemia vera.